放化疗联合治疗食管癌患者的临床疗效与预后研究

Study on the Clinical Efficacy and Prognosis of Combined Radiotherapy and Chemotherapy in the Treatment of Patients with Esophageal Cancer

目的 分析在食管癌患者的临床治疗中对患者采取放化疗联合治疗的临床疗效。方法 将德州市中医院于2017年1月-2019年12月治疗的20例食管癌患者作为本次研究对象,所有患者均经由临床检查确诊,并分析患者在治疗前后的ADL、QOL评分、毒副反应发生情况,治疗后患者的临床疗效以及在治疗后患者的远期生存率。结果 分析患者的远期生存率可见,患者在半年内的生存率达到了80%,而患者一年生存率达到70%,在治疗两年后患者生存率为45%;分析患者的临床疗效可见,治疗显效患者10例,治疗有效患者的7例,治疗总有效率为85%;治疗后患者出现1例患者出现骨髓抑制现象,4例患者发生恶心、呕吐等症状,另有2例患者出现肝损伤,1例患者出现黏膜炎及放射性肺炎,总发生率为40%;而在患者治疗前后的ADL、QOL评分对比中可见,治疗后患者的ADL、QOL评分明显更高于治疗前,对比统计学差异明显(P<0.05)。结论 在食管癌患者的临床治疗中,对患者采取放化疗联合治疗能够有效提高患者的临床疗效,适当增加放疗剂量与化疗剂量能够帮助临床控制患者的疾病进展,同时不会增加毒副反应,治疗后患者的生活质量相对更高,值得临床广泛应用。

Objective To analyze the clinical efficacy of combined radiotherapy and chemotherapy in the clinical treatment of patients with esophageal cancer.Methods Twenty patients with esophageal cancer who were treated in our hospital from January 2017 to December 2019 were selected as the subjects of this study.All patients were diagnosed through clinical examination,and the patients’ ADL,QOL scores,and side effects before and after treatment were analyzed.Occurrence,clinical efficacy of patients after treatment and long-term survival rate of patients after treatment.Results Analysis of the patient’s long-term survival rate shows that the patient’s survival rate reached 80% within half a year,while the patient’s one-year survival rate reached 70%,and the patient’s survival rate after two years of treatment was 45%;Analysis of the patient’s clinical efficacy shows that,there were 10 patients with markedly effective treatment and 7 patients with effective treatment.The total effective rate of treatment was 85%.After treatment,1 patient developed bone marrow suppression,4 patients developed nausea,vomiting and other symptoms,and 2 patients developed liver Injury,mucositis and radiation pneumonitis occurred in 1 patient,with a total incidence of 40%;And in the comparison of the ADL and QOL scores before and after treatment,it can be seen that the ADL and QOL scores of the patients after treatment were significantly higher than those before treatment.Comparative statistics The academic difference is obvious (P<0.05).Conclusion In the clinical treatment of patients with esophageal cancer,the combination of radiotherapy and chemotherapy can effectively improve the clinical efficacy of patients.Appropriately increasing the dose of radiotherapy and chemotherapy can help clinically control the patient’s disease progression without increasing toxic and side effects.The quality of life of patients is relatively higher,which is worthy of clinical application.